FDA Approves Zurzuvae: First Oral Pill for Postpartum Depression in the US
The US Food and Drug Administration (FDA) has approved zuranolone, the first oral pill specifically for postpartum depression in the United States. Sold under the brand name Zurzuvae, the once-daily pill is taken over a 14-day course. Postpartum depression affects about 1 in 7 new mothers and can have serious consequences for both the mother and child. The medication, which is a version of a naturally occurring substance in the body, has shown rapid relief of symptoms in clinical trials. However, some experts raise concerns about its use for mild to moderate depression and emphasize the importance of psychotherapy and addressing social determinants of health.
- FDA approves first postpartum depression pill in the US CNN
- FDA approves first postpartum depression drug, Zurzuvae The Washington Post
- FDA approves first pill to treat postpartum depression PBS NewsHour
- FDA Approves First Pill for Postpartum Depression The New York Times
- FDA approves oral pill for postpartum depression for first time Reuters
Reading Insights
0
1
8 min
vs 9 min read
94%
1,664 → 105 words
Want the full story? Read the original article
Read on CNN